Genotype-Guided Iloperidone Dosing for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic treatments for schizophrenia are highly variable in patient response, leading to a high discontinuation rate and lack of guidance for selecting the most appropriate medication and dosage for individual patients, as pharmacogenomics data for genetic markers predictive of response are limited.
Innovation Solution
The method involves determining an individual's genotype at specific single nucleotide polymorphisms (SNPs) associated with the dopamine receptor D2 and ankyrin repeat and kinase domain containing 1 genes to predict the efficacy of iloperidone treatment for psychotic symptoms, allowing for personalized dosing adjustments, such as administering a lower or higher dose based on genotype-related efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotic drugs are used to treat schizophrenia, then psychotic symptoms can be managed, but patient response remains highly variable and discontinuation rate is high
Solution Approach 1:
The patent applies parameter changes by utilizing genetic markers (SNPs in DRD2 and ANKK1 genes) to modify treatment parameters. By determining a patient's genotype at specific SNP loci, clinicians can adjust antipsychotic dosage or selection to match individual genetic profiles, transforming the treatment approach from a one-size-fits-all model to a personalized model based on genetic parameters
Solution Approach 2:
The patent implements self-service by enabling patients to provide their own genetic information through saliva or blood samples. The genetic testing allows patients to participate actively in their treatment decision-making process, with their genetic profile serving as the basis for selecting the most appropriate antipsychotic medication and dosage without requiring extensive trial-and-error
2Reliability
If multiple antipsychotic agents are tried to find optimal effect, then treatment specificity can be improved, but time and resources are consumed through trial and error
Solution Approach 1:
The patent applies preliminary action by performing genetic testing before initiating antipsychotic treatment. By determining the patient's genotype at DRD2 and ANKK1 SNP loci in advance, clinicians can predict which antipsychotic agent is most likely to be effective and select it as the initial treatment, eliminating the need for time-consuming trial-and-error approaches
3Ease of operation
If standard dosing is used for all patients, then treatment administration is simplified, but treatment efficacy varies significantly between individuals
Solution Approach 1:
The patent applies parameter changes by adjusting dosage parameters based on genetic profiles. Patients with certain SNP genotypes (e.g., A1/A2 at rs1800497) may receive reduced doses, while others receive standard or higher doses. This maintains ease of operation through clear genotype-dose guidelines while significantly improving treatment efficacy through personalized dosing
Data Source
AI summary
The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.